The Society of Surgical Oncology, inc.
The American Society of Breast Surgeons.
Annals of Surgical Oncology

Log in | Register

Clinical Significance of C-MET Overexpression and Epidermal Growth Factor Receptor Mutation in Platinum-Based Adjuvant Chemotherapy Outcome in Surgically Resected Lung Adenocarcinoma

In-Ho Kim MD, In Hee Lee MD, Ji Eun Lee MD, Sook Hee Hong MD, PhD, Tae-Jung Kim MD, Kyo-Young Lee MD, PhD, Young Kyoon Kim MD, PhD, Seung Joon Kim MD, PhD, Sook Whan Sung MD, PhD, Jae Kil Park MD, PhD, Ie Ryung Yoo MD, PhD, Yeon Sil Kim MD, PhD, Jung-Oh Kim MS, Jin Hyoung Kang MD, PhD
Thoracic Oncology
Volume 24, Issue 3 / March , 2017

Abstract

Purpose

We retrospectively assessed the role of C-MET expression and epidermal growth factor receptor (EGFR) mutation on survival following platinum-based adjuvant chemotherapy. The impact of C-MET on survival was also investigated in relation to EGFR mutation status.

Methods

We enrolled 311 patients with resected lung adenocarcinoma (high-risk stage 1B–3A), and performed immunohistochemistry (IHC) using C-MET- and mutant EGFR (EGFRmut)-specific antibodies in tissue microarrays.

Results

Adjuvant chemotherapy was administered to 151 patients, 96 of whom relapsed and 85 died by the end of the study. On IHC, C-MET and EGFRmut were positive in 141 (45.3 %) and 88 (28.3 %) cases, respectively. On univariate analysis, adjuvant chemotherapy prolonged relapse-free survival (RFS) and overall survival (OS) in C-MET(+) patients (RFS p = 0.035; OS p = 0.013) but not in C-MET(−) patients. On multivariate analysis, adjuvant chemotherapy was a positive independent prognostic factor in C-MET(+) (RFS p = 0.013; OS p = 0.006) but not in C-MET(−) patients. In addition, univariate analysis showed no effect of EGFRmut status on RFS and OS after chemotherapy, whereas multivariate analysis revealed that adjuvant chemotherapy increased RFS in both EGFRmut(+) and EGFRmut(−) patients [EGFRmut(+) p = 0.033; EGFRmut(−) p = 0.030]. C-MET was a negative prognostic factor for RFS (p = 0.045) and OS (p = 0.007) in the EGFRmut(−) group but not in the EGFRmut(+) group, on multivariate analysis.

Conclusions

Our data indicate that patients with C-MET overexpression should be considered for adjuvant chemotherapy, and that C-MET negatively correlates with survival in patients with wild-type, but not mutant, EGFR.

Add a comment



0 comment(s)